Baxalta
Baxalta is a biopharmaceutical company focused on developing innovative therapies for conditions such as hemophilia, bleeding disorders, immune deficiencies, and alpha-1 antitrypsin deficiency. Its products are available in over 100 countries, supported by biological manufacturing operations across 12 facilities that specialize in recombinant production and plasma fractionation. In addition to its core business, Baxalta Ventures invests in healthcare companies that are creating novel products and therapies, leveraging its expertise in pharmaceuticals, medical devices, and biotechnology. The venture team emphasizes building strong relationships with entrepreneurs and industry experts to support the growth of portfolio companies. By fostering strategic alliances and utilizing Baxalta’s capabilities in clinical development, production, and marketing, Baxalta Ventures seeks to enhance the commercialization of innovative therapeutic solutions. The company typically makes initial investments of up to $5 million, with potential for increased funding as the company matures.
Syntimmune, Inc. is a clinical-stage biotechnology company based in Boston, Massachusetts, focused on developing innovative drug candidates for a variety of autoimmune diseases. Founded in 2013 by Laurence and Richard Blumberg, Syntimmune leverages its expertise in the biology of the neonatal Fc receptor (FcRn) to advance novel therapies targeting IgG-mediated autoimmune conditions. The company's platform centers on creating humanized monoclonal antibodies that inhibit the interaction between FcRn and Immunoglobulin G (IgG), aiming to provide transformative treatments for patients suffering from rare IgG-mediated diseases. As of November 2018, Syntimmune operates as a subsidiary of Alexion Pharmaceuticals, Inc.
Syntimmune, Inc. is a clinical-stage biotechnology company based in Boston, Massachusetts, focused on developing innovative drug candidates for a variety of autoimmune diseases. Founded in 2013 by Laurence and Richard Blumberg, Syntimmune leverages its expertise in the biology of the neonatal Fc receptor (FcRn) to advance novel therapies targeting IgG-mediated autoimmune conditions. The company's platform centers on creating humanized monoclonal antibodies that inhibit the interaction between FcRn and Immunoglobulin G (IgG), aiming to provide transformative treatments for patients suffering from rare IgG-mediated diseases. As of November 2018, Syntimmune operates as a subsidiary of Alexion Pharmaceuticals, Inc.
Gadeta B.V. is a research and development company based in Utrecht, the Netherlands, focused on creating immunotherapies for cancer. Founded in 2015, Gadeta has developed a technology platform utilizing combinatorial T Cell receptor exchange (CTE) to create optimized gamma delta (γδ) T-cell receptors (TCRs) that enhance anti-cancer reactivity. The company’s key product, T Cells Engineered To Express A Defined Gamma Delta TCR (TEGs), shows strong therapeutic potential against both hematological and solid tumors by employing high-affinity γδ TCRs expressed on αβ T cells, which possess superior proliferation capabilities. Gadeta has also established a strategic collaboration with Kite Pharma to further advance its innovations in cancer treatment.
Syntimmune, Inc. is a clinical-stage biotechnology company based in Boston, Massachusetts, focused on developing innovative drug candidates for a variety of autoimmune diseases. Founded in 2013 by Laurence and Richard Blumberg, Syntimmune leverages its expertise in the biology of the neonatal Fc receptor (FcRn) to advance novel therapies targeting IgG-mediated autoimmune conditions. The company's platform centers on creating humanized monoclonal antibodies that inhibit the interaction between FcRn and Immunoglobulin G (IgG), aiming to provide transformative treatments for patients suffering from rare IgG-mediated diseases. As of November 2018, Syntimmune operates as a subsidiary of Alexion Pharmaceuticals, Inc.
True North Therapeutics, Inc. is a biotechnology company focused on developing therapies that target the complement pathway of the immune system, specifically for rare diseases with high unmet clinical needs. Founded in 2013 and based in South San Francisco, California, the company’s lead product, TNT009, is a monoclonal antibody designed to selectively inhibit the classical complement pathway. This approach aims to prevent inflammatory mediators and phagocytosis in conditions such as cold agglutinin disease, warm autoimmune hemolytic anemia, and other complement-mediated disorders. True North is also exploring additional treatment options for a variety of diseases in hematology, dermatology, and neurology. The company operates as a subsidiary of Bioverativ Inc.
Syntimmune, Inc. is a clinical-stage biotechnology company based in Boston, Massachusetts, focused on developing innovative drug candidates for a variety of autoimmune diseases. Founded in 2013 by Laurence and Richard Blumberg, Syntimmune leverages its expertise in the biology of the neonatal Fc receptor (FcRn) to advance novel therapies targeting IgG-mediated autoimmune conditions. The company's platform centers on creating humanized monoclonal antibodies that inhibit the interaction between FcRn and Immunoglobulin G (IgG), aiming to provide transformative treatments for patients suffering from rare IgG-mediated diseases. As of November 2018, Syntimmune operates as a subsidiary of Alexion Pharmaceuticals, Inc.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.